Can the exacerbated synthesis of inflammatory markers in COVID-19 impair the response to treatments in patients with coronavirus?
DOI:
https://doi.org/10.33448/rsd-v11i11.33562Keywords:
COVID-19; Pandemic; SARS-CoV-2; Inflammatory markers.Abstract
In addition to chronic diseases and empirical therapies against COVID-19, other factors are responsible for the high mortality rate associated with COVID-19. The objective of this study was to verify whether the exacerbated synthesis of inflammatory markers resulting from COVID-19 could compromise patients with coronavirus. The bibliographic research was performed in the Pubmed, LILACS, and SciELO databases between December 2020 and July 2021. For this study, the terms "COVID-19," "Biomarkers," "SARS-COV-2," and “Coronavirus 2019" are in advanced mode to gather the best evidence for the proposal of this manuscript. In the present construct, it is argued that COVID-19 increases the susceptibility of patients to a high stage of inflammation, increasing the virulence factors of the virus and its dissemination through the human body, where the synthesis of inflammatory factors plays a crucial role in the worsening of the cases. The virulence of the virus can be decreased by correcting the synthesis of these inflammatory markers, as it can prevent a less ineffective immune response and even increase the resistance of patients. Consequently, clinical trials in this direction should be carried out from the perspective of modulating responses at the molecular level, to find out how they work and how the underexpression of inflammatory cytokines may reduce the aggravation of patients with coronavirus.
References
Bertolini, A., van de Peppel, I. P., Bodewes, F. A. J. A., Moshage, H., Fantin, A., Farinati, F., Fiorotto, R., Jonker, J. W., Strabosco, M., & Verkade, H. J., Peserico, G. (2020). Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis Epidemiology of Abnormal LFTs in Patients With COVID-19. Hepatology, 72(5), 1864-1872. https://doi.org/10.1002/hep.31480
Cheng, L., Li, H., Li, L., Liu, C., Yan, S., Chen, H., & Li, Y. (2020). Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Journal of Clinical Laboratory Analysis, 34(10), e23618. https://doi.org/10.1002/jcla.23618
Fakhroo, A. D., Thani, A. A. A., & Yassine, H. M. (2021). Markers Associated with COVID-19 Susceptibility, Resistance, and Severity. Viruses, 13(1), 45.= https://doi.org/10.3390/v13010045
Garg, M., Sharma, A. L., & Singh, S. (2021). Advancement in biosensors for inflammatory biomarkers of SARS-CoV-2 during 2019-2020. Biosensors and Bioelectronics, 171(1), 112703. https://doi.org/10.1016%2Fj.bios.2020.112703
Hadid, T., Kafri, Z., & Al-Katib, A. (2021). Coagulation and anticoagulation in COVID-19. Blood Reviews, 47, 100761. https://doi.org/10.1016/j.blre.2020.100761
Hariyanto, T. I., Japar, K. V., Kwenandar, F., Damay, V., Siregar, J. I., Lugito, N. P. H., Tjiang M. M., & Kurniawan, A. (2021). Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis. American Journal of Emergency Medicine, 41(1), 110-119. https://doi.org/10.1016/j.ajem.2020.12.076
Hill, J. A., Menon, M. P., Dhanireddy, S., Wurfel, M. M., Green, M., Jain, R., Chan J. D., Huang, J., Bethune, D., Turtle, C., et al. (2021). Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. Journal of Medical Virology, 93(4), 2270-2280. https://doi.org/10.1002/jmv.26674
Iba, T., Levy, J. H., Levi, M., & Thachil, J. (2020). Coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis, 8(9), 2103-2109. https://doi.org/10.1111/jth.14975
Iwamura, A. P. D., da Silva, M. R. T., Hümmelgen, A. L, Pereira, P. V. S., Falcai, A., Grumach, A. S., Goudouris, E., Neto, A. C., & Prando, C. (2021). Immunity and inflammatory biomarkers in COVID-19: A systematic review. Reviews in Medical Virology, 31(4), e2199. https://doi.org/10.1002/rmv.2199
Lakkireddy, M., Gadiga, S. G., Malathi, R. D., Karra, M. L., Raju, I. S. S. V. P. M., Ragini., Chinapaka, S., Baba, K. S. S. S., & Kandakatla, M. (2021). Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease. Scientific Reports, 11(1), 10641. https://doi.org/10.1038/s41598-021-90189-4
Luan, Y. Y., Yin, C. H., & Yao, Y. M. (2021). Update Advances on C-Reactive Protein in COVID-19 and Other Viral Infections. Frontiers in Immunology, 12, 720363. https://doi.org/10.3389/fimmu.2021.720363
Martinez-Urbistondo, M., Mora-Vargas, A., Expósito-Palomo, E., Castejón, R., Citores, M. J., Rosado, S., de Medonza, C., Bãnos, I., Fernández-Cruz, A., Daimiel, L., San-Cristóbal, R., & Vargas, J. A. (2020). Inflammatory-related clinical and metabolic outcomes in Covid-19 patients. Mediators of Inflammation, 2020, 2914275. https://doi.org/10.1155/2020/2914275.
McNeill, J. N., Lau, E. S., Paniagua, S. M., Liu, E.E., Wang, J. K., Bassett, I. V., Selvaggi, C. A., Lubitz, S. A., Foulkes, A. S., & Ho J. E. (2021). The role of obesity in inflammatory markers in COVID-19 patients. Obesity Research and Clinical Practice, 15(1), 96-99. https://doi.org/10.1016/j.orcp.2020.12.004
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet, 395(10229), 1033-1034. https://doi.org/10.1016/s0140-6736(20)30628-0
Ponti, G., Maccaferri, M., Ruini, C., Tomasi, A., & Ozben, T. (2020). Biomarkers associated with COVID-19 disease progression. Critical Reviews in Clinical Laboratory Sciences. Taylor and Francis Ltd, 57(6), 389-399. https://doi.org/10.1080/10408363.2020.1770685
Sabbatinelli, J., Giuliani, A., Matacchione, G., Latini, S., Laprovitera, N., Pomponio, G., Ferrarini, A., Baroni, S. S., Pavani, M., Moretti, M., Gabrielli, A., Procopio, A. D., Ferracim, M., Bonafé, M., & Olivieri, F. (2021). Decreased serum levels of the inflammaging marker miR-146a are associated with non-clinical response to tocilizumab in COVID-19 patients. Mechanisms of Ageing and Development. 2021 Jan 1;193
Santos, L. G., Baggio, J. A. O., Leal, T. C., Costa, F. A., Fernandes, T. R. M. O., da Silva R. V., Armstrong A., Carmo R. F., & de Souza C. D. F. (2021). Prevalence of Systemic Arterial Hypertension and Diabetes Mellitus in Individuals with COVID-19: A Retrospective Study of Deaths in Pernambuco, Brazil. Arquivos Brasileiros de Cardiologia, 117(2), 416-422. https://doi.org/10.36660/abc.20200885
Satış, H., Özger, H. S., Yıldız, P. A., Hızel, K., Gulbahar, Ö., Erbaş, G., Aygencel, G., Tunccan, O. G., Öztürk, M. A., Dizbay, M., & Tufan, A. (2021). Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19. Cytokine, 137(1), 155302. https://doi: https://doi.org/10.1016/j.cyto.2020.155302
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Boll, B., & von Bergwelt-Baildon, M. S. (2018). Cytokine release syndrome. Journal of Immunothepary of Cancer, 6(56), 1-14. https://doi.org/10.1186/s40425-018-0343-9
Smilowitz, N. R., Kunichoff, D., Garshick, M., Shah, B., Pillinger, M., Hochman, J. S, & Berger, J. S. (2021). C-reactive protein and clinical outcomes in patients with COVID-19. European Heart Journal, 42(23), 2270-2279. https://doi.org/10.1093/eurheartj/ehaa1103
Smith, M., Lara, O. D., O’Cearbhaill, R., Knisely, A., McEachron, J., Gabor, L., Carr, C., Blank, S., Prasad-Hayes, M., Frey, M., et al. (2020). Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection. Gynecologic Oncology, 159(3), 618-622. https://doi.org/10.1016/j.ygyno.2020.09.036
Lughetti, L., Trevisani, V., Cattini, U., Bruzzi, P., Lucaccioni, L., Madeo, S., & Predieri, B. (2020). COVID-19 and Type 1 Diabetes: Concerns and Challenges. Acta Biomedica, 91(3), 2020033. https://doi.org/10.23750/abm.v91i3.10366
Pelle, M. C., Tassone, B., Ricchio, M., Mazzitelli, M., Davoli, C., Procopio, G., Cancelliere, A., La Gamba, V., Lio, E., & Matera, G, et al. (2020). Late-onset myocardial infarction and autoimmune haemolytic anaemia in a COVID-19 patient without respiratory symptoms, concomitant with a paradoxical increase in inflammatory markers: a case report. Journal of Medical Case Reports, 14(26), 1-6. https://doi.org/10.1186/s13256-020-02595-3
Pu, S. L., Zhang, X. Y., Liu, D. S., Ye, B. N., & Li, J. Q. (2021). Unexplained elevation of erythrocyte sedimentation rate in a patient recovering from COVID-19: A case report Conflict-of-interest statement. World Journal of Clinical Cases, 9(6):1394-1401. http://dx.doi.org/10.12998/wjcc.v9.i6.1394
Saumtally, H., Cassidy, S., Lal, S., & Khan, E. (2021). Covid-19, Sixteen Months Into The Pandemic: A Narrative Review. Journal of Ayub Medical College, Abbottabad, 33(4), 673-684.
Upadhyay, J., Tiwari, N., & Ansari, M. N. (2020). Role of inflammatory markers in corona virus disease (COVID-19) patients: A review. Experimental Biology and Medicine, 245(15), 1368-1375. https://doi.org/10.1177/1535370220939477
Yang, Q., Hughes, T. A., Kelkar, A., Yu, X., Cheng, K., Park, S. J., Huang, W. C., Lovell, J. F., & Neelamegham, S. (2020). Inhibition of SARS-CoV-2 viral entry upon blocking N-and O-glycan elaboration. ELife, 9, e61552. https://doi.org/10.7554/elife.61552
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Glensimon Souza Silva Cavalcante; Maria Conceição Santana dos Santos; Mirelle de Sousa Braga; Gisele Rosada Dônola Furtado; Krisley Rodrigues Lima Pereira; Erika Elita Araújo Lessa; Kledson Lopes Barbosa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
